Acurx Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm Colin Minicus, I'm an associate here at JPMorgan's Healthcare Group. It's my pleasure to welcome Acurx to the 42nd Annual JPMorgan Healthcare Conference. As a reminder, we'll plan to hold Q&A at the end of today's session.
Without further ado, please welcome CEO, Dave Luci.
Thank you, Colin, and thank you to our host at JPMorgan for this opportunity. We're delighted to be here today. We'll have a Q&A after a brief presentation, and we look forward to any questions.
Today, we will have forward-looking statements, and we do refer folks to our SEC filings for our 10-Qs and 10-Ks and historical information.
Our executive summary, Acurx Pharmaceuticals, NASDAQ ticker ACXP, is developing a new class of antibiotics to treat difficult-to-treat Gram-positive bacterial infections with a lead antibiotic candidate targeting the treatment of C. difficile infection and moving into Phase III. It
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
